ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IMNM vs PVLA // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Immunome Inc. (NASDAQ) VS. Palvella Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IMNM 2 — PVLA 3
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMNM VS. PVLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IMNM PVLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -27.90% -7.10 PVLA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.29% -1.14% -8.15 PVLA /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -23.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 25.03 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 IMNM /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.7 57.6 -17.90 PVLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.15B $2.11B $43.0M IMNM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IMNM REV PVLA REV IMNM GROSS % PVLA GROSS % IMNM FCF PVLA FCF
FY 2025 $6.9M $108.1M — — -$200.6M -$25.0M
FY 2024 $9.0M $39.5M — — -$118.0M -$10.8M
FY 2023 $14.0M $42.8M — — -$7.6M -$13.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMNM // BETA —
PVLA // BETA —